Ranbaxy Laboratories Limited (Ranbaxy) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of UK, and the Therapeutic Goods Administration (TGA), Department of Health and Ageing of the Australian Government, have issued Good Manufacturing Practice (GMP) certificates for its manufacturing site at Paonta Sahib (India), following a joint audit conducted in October 2008. The MHRA approval will not only cover product filings for the UK but will also apply to product filings for the entire European Union.

Both authorities had inspected this facility in 2006 and had found it to be compliant with the respective principles and guidelines of GMP. GMP certificates valid up to two years were issued.

Subsequent to the routine re-audit in November 2008 conducted by these authorities, GMP certification has been extended for a further three years by the MHRA and for two years by the TGA.

Ranbaxy remains committed to providing high quality generic medicines at affordable prices to its customers and patients in Europe, Australia and the entire global marketplace.